EUVIMEDEUVIMED entdecken
Crossref

EFFICACY AND SAFETY OF NERVE SANJEEVANI AYURVEDIC CAPSULE IN PATIENTS WITH SCIATICA: AN EXPLORATORY OPEN-LABEL CLINICAL STUDY

Vijay Kimtata, Hasan Ali Ahmed, Lokesh Holagundi

International Journal of Research in Ayurveda and Pharmacy · 30.10.2026 · 17 (5) · 46-51

DOI: 10.7897/2277-4343.175172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Research in Ayurveda and Pharmacy, online erschienen am 30.10.2026. Verfasst von Vijay Kimtata und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sciatica is characterized by radiating pain, functional impairment, and decreased health-related quality of life. This study was performed to assess the efficacy and safety of Nerve Sanjeevani, a proprietary Ayurvedic herbo-mineral formulation, in patients with sciatica.

Methods

This open-label, non-randomized, single-arm exploratory study enrolled 52 adults with sciatica. All the participants were given Nerve Sanjeevani Capsule (650 mg) orally twice a day for 14 days. The efficacy was measured by Numeric Rating Scale (NRS), Roland-Morris Disability Questionnaire for Sciatica (RMDQ-S), Sciatica Bothersomeness Index (SBI), Global Perceived Change (GPC) and Short Form-36(SF-36). Safety evaluations included vital signs, hematology and biochemical analysis, and adverse event assessment.

Results

Fifty participants completed the study and were included in the efficacy analysis. Significant reductions were observed in NRS, RMDQ-S, and SBI scores (p < 0.0001). GPC scores also reduced significantly (p < 0.0001). SF-36 scores showed significant improvements in physical functioning and vitality. Significant changes were also observed in other domains, including role limitations, emotional well-being, social functioning, pain, and general health. Six mild adverse events were reported; however, none were considered likely to be related to the study product.

Conclusion

Nerve Sanjeevani was associated with significant improvements in pain, functional disability, and sciatica-related symptom burden over 14 days. The uncontrolled design and short treatment period limit causal conclusions and long-term safety assessment. Further randomized controlled studies with longer follow-up are warranted.

Zitieren

APA

Kimtata, V., Ahmed, H. A., & Holagundi, L. (2026). EFFICACY AND SAFETY OF NERVE SANJEEVANI AYURVEDIC CAPSULE IN PATIENTS WITH SCIATICA: AN EXPLORATORY OPEN-LABEL CLINICAL STUDY. International Journal of Research in Ayurveda and Pharmacy, 17(5), 46-51. https://doi.org/10.7897/2277-4343.175172

Vancouver

Kimtata V, Ahmed HA, Holagundi L. EFFICACY AND SAFETY OF NERVE SANJEEVANI AYURVEDIC CAPSULE IN PATIENTS WITH SCIATICA: AN EXPLORATORY OPEN-LABEL CLINICAL STUDY. International Journal of Research in Ayurveda and Pharmacy. 2026;17(5):46-51. doi:10.7897/2277-4343.175172

BibTeX
@article{Kimtata2026,
  author = {Kimtata, Vijay and Ahmed, Hasan Ali and Holagundi, Lokesh},
  title = {EFFICACY AND SAFETY OF NERVE SANJEEVANI AYURVEDIC CAPSULE IN PATIENTS WITH SCIATICA: AN EXPLORATORY OPEN-LABEL CLINICAL STUDY},
  journal = {International Journal of Research in Ayurveda and Pharmacy},
  year = {2026},
  volume = {17},
  number = {5},
  pages = {46--51},
  doi = {10.7897/2277-4343.175172}
}
Kostenlos starten →